State of Alaska Department of Revenue Has $247,000 Stake in Fulgent Genetics, Inc. (NASDAQ:FLGT)

State of Alaska Department of Revenue decreased its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 4.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,411 shares of the company’s stock after selling 536 shares during the quarter. State of Alaska Department of Revenue’s holdings in Fulgent Genetics were worth $247,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in FLGT. Millennium Management LLC increased its holdings in shares of Fulgent Genetics by 34.3% in the second quarter. Millennium Management LLC now owns 958,852 shares of the company’s stock worth $18,813,000 after acquiring an additional 244,981 shares in the last quarter. Divisadero Street Capital Management LP grew its holdings in shares of Fulgent Genetics by 46.4% during the second quarter. Divisadero Street Capital Management LP now owns 505,212 shares of the company’s stock worth $9,912,000 after buying an additional 160,212 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Fulgent Genetics by 37.6% during the second quarter. Bank of New York Mellon Corp now owns 201,201 shares of the company’s stock worth $3,948,000 after buying an additional 55,020 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Fulgent Genetics by 593.5% during the second quarter. Acadian Asset Management LLC now owns 62,724 shares of the company’s stock worth $1,227,000 after buying an additional 53,680 shares in the last quarter. Finally, Acuitas Investments LLC bought a new position in shares of Fulgent Genetics during the second quarter worth about $962,000. Institutional investors and hedge funds own 48.06% of the company’s stock.

Insider Buying and Selling

In related news, CEO Ming Hsieh sold 2,313 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $22.83, for a total transaction of $52,805.79. Following the completion of the transaction, the chief executive officer now directly owns 707,275 shares in the company, valued at approximately $16,147,088.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders sold 4,324 shares of company stock worth $98,717. 31.76% of the stock is owned by corporate insiders.

Fulgent Genetics Stock Performance

NASDAQ:FLGT opened at $19.43 on Friday. The company has a market cap of $588.67 million, a PE ratio of -3.52 and a beta of 1.51. Fulgent Genetics, Inc. has a 52-week low of $18.76 and a 52-week high of $30.68. The stock has a 50-day simple moving average of $21.01 and a 200 day simple moving average of $21.43.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.